C2N Diagnostics, a specialty diagnostics company focused on brain health, announced a significant expansion of its St. Louis headquarters. The company will triple its operational space, moving to a new facility at 4140 Forest Park Avenue in the Cortex Innovation District. This move will consolidate the company’s operations under one roof.
The new headquarters will be located within the Catalyst building, a redeveloped site in Midtown St. Louis. C2N will occupy 82,451 square feet, encompassing three floors. The company plans to complete the move by late 2026. The new space will incorporate advanced bioautomation and high-throughput proteomic testing technologies.
C2N will maintain its existing laboratory, transitioning it into a center for multi-omic solutions and advanced analytical platforms. This will support the company’s biopharmaceutical research services, medtech business units, and international collaborations.
Dr. Joel Braunstein, C2N‘s CEO, attributed the expansion to strong local support, a talented workforce, and the adoption of the company’s testing services by healthcare professionals. He expressed excitement about growing within the Cortex Innovation District, highlighting its resources and commitment to innovation.
Missouri Governor Mike Kehoe praised C2N‘s success, viewing it as evidence of the state’s leadership in medical research. He emphasized the positive impact of the company’s partnership with Washington University.
C2N‘s growth is fueled by its innovative blood tests for Alzheimer’s disease, including the PrecivityAD2™ test, which aids in the detection of amyloid plaques. The company utilizes advanced liquid-chromatography-tandem mass spectrometry (LC-MS/MS) methodologies and possesses extensive expertise in neurological science.
The company’s Precivity™ biomarkers have been cited in over 50,000 peer-reviewed publications, resulting from more than 150 collaborations. C2N is expanding its biomarker pipeline to include assays for tau pathology and Parkinson’s disease research, and is developing technologies to decentralize mass spectrometry testing.
Recent achievements include an investment from Samsung, a partnership with The Michael J. Fox Foundation, medical device registration in the United Kingdom, and Canadian expansion.
Doug Frantz, vice chancellor for innovation and commercialization at Washington University, highlighted the university’s role in supporting C2N’s growth, noting that the company was co-founded by WashU researchers. He emphasized that Catalyst offers the resources necessary for late-stage startups to accelerate their progress.
Dustin Allison, Interim CEO of Greater St. Louis, Inc., emphasized the expansion’s importance to both human health and economic development in the region. He highlighted the supportive business environment in St. Louis.
C2N acknowledged the support of various entities, including the City of St. Louis, the Cortex Innovation District, and the Missouri Department of Economic Development. The company currently operates out of facilities within the Cortex Innovation District.
C2N Diagnostics provides clinical laboratory services and diagnostic solutions in brain health, utilizing mass spectrometry-based biomarker services and products for clinical decision-making, clinical trial optimization, and healthcare research. The company’s assays have been used in numerous Alzheimer’s disease studies globally and it collaborates extensively with pharmaceutical companies, academic institutions, and research organizations.
Related
